Sunshine Biopharma Return On Equity vs. Current Valuation
| SBFM Stock | USD 3.04 0.60 24.59% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (0.21) | Current Value (0.20) | Quarterly Volatility 85.97970435 |
For Sunshine Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sunshine Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sunshine Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sunshine Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sunshine Biopharma over time as well as its relative position and ranking within its peers.
Sunshine |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share 197.42 | Quarterly Revenue Growth 0.416 | Return On Assets (0.11) | Return On Equity (0.18) |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Sunshine Biopharma Current Valuation vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sunshine Biopharma's current stock value. Our valuation model uses many indicators to compare Sunshine Biopharma value to that of its competitors to determine the firm's financial worth. Sunshine Biopharma is currently regarded as top stock in return on equity category among its peers. It is rated below average in current valuation category among its peers . At this time, Sunshine Biopharma's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Sunshine Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Sunshine Current Valuation vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Sunshine Biopharma |
| = | -0.18 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Sunshine Biopharma |
| = | (6.76 M) |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Sunshine Current Valuation vs Competition
Sunshine Biopharma is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 522.12 Million. Sunshine Biopharma has negative current valuation of (6.76 Million) having no influence on the industry.
Sunshine Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sunshine Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sunshine Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Sunshine Biopharma's change in net profit over the period of time. It can combine multiple indicators of Sunshine Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 696.1 K | 730.9 K | |
| Operating Income | -4.8 M | -4.5 M | |
| Income Before Tax | -4.1 M | -4.3 M | |
| Net Loss | -4.5 M | -4.7 M | |
| Income Tax Expense | 395.2 K | 414.9 K | |
| Total Other Income Expense Net | 674.4 K | 708.1 K | |
| Net Loss | -26.8 M | -25.4 M | |
| Net Loss | -24.1 M | -22.9 M | |
| Net Interest Income | 602.3 K | 632.4 K | |
| Interest Income | 736 K | 460 K | |
| Change To Netincome | 21.1 M | 22.1 M | |
| Net Loss | (370.41) | (388.93) | |
| Income Quality | 1.95 | 2.04 | |
| Net Income Per E B T | 1.10 | 0.77 |
Sunshine Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sunshine Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sunshine Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sunshine Biopharma's important profitability drivers and their relationship over time.
Use Sunshine Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sunshine Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sunshine Biopharma will appreciate offsetting losses from the drop in the long position's value.Sunshine Biopharma Pair Trading
Sunshine Biopharma Pair Trading Analysis
The ability to find closely correlated positions to Sunshine Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sunshine Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sunshine Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sunshine Biopharma to buy it.
The correlation of Sunshine Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sunshine Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sunshine Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sunshine Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Sunshine Biopharma position
In addition to having Sunshine Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Blockchain Thematic Idea Now
Blockchain
Companies across muliple sectors and different technology products and services that are engaged in some capacity with blockchain technolgoy or evolution of cryptocurrency. The Blockchain theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Blockchain Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
To fully project Sunshine Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sunshine Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sunshine Biopharma's income statement, its balance sheet, and the statement of cash flows.